Slide 1: Radiolabeled antibody targeting prostate-specific membrane antigen (PSMA)
Exhibit 99.7 “Radiolabeled Howard Chief, Memorial New York, Genitourinary I. Sloan-Kettering Scher, NY7E11MDantibody Oncology Cancer targeting Service Center prostate-specific membrane antigen (PSMA)”
Slide 2: Prostate-Specific Membrane Antigen
Prostate-Specific Type Expressed Over-expressed Also Source: tail Cytoplasmic membrane Cell region Extracellular specific functional Slide found II # 2membrane Schulke membrane target ininall thein forms N, for Membrane neovasculature carcinoma bound antigen Varlamova cancer of prostate glycoprotein
Slide 3: Radiotherapy Product Candidate: 7E11.C5.3 linked to Lu-177
Radiotherapy Proprietary Recognizes Linked 7E11.C5.3 S H L u 1 7 + 3 N C eM Olide # 3to amAb 7E11 therapeutic anProduct intracellular murine Candidate radionuclide monoclonal epitope (Lu-177) antibodyusing directed MeO-DOTA against PSMA by
Slide 4: ProstaScint 7E11 and IND filing expected Q1 2006
ProstaScint 7E11 When IND Slidefiling #monoclonal Monoclonal linked 4 expected (7E11.C5.3) to a therapeutic antibody Antibody in Q1 monoclonal 2006 has radionuclide established antibody can intellectual has deliver beenlethal property safely dose administered of radiationtotomore target than cells 6
Slide 5: Rationale for radiolabeled 7E11 mAb
Solid #human Commercial Radiolabeled Murine Fully Intracellular Malignant Slide Rationale 5mAbtumors epitope products or preferable molecules humanizing contain target for have abnormally validated radiotherapy prolongs provenbysuccessful the permeable ProstaScint® plasmafor half-life degenerating t
Slide 6: Preclinical Data: PSMA expression in LNCaP tumor mice
Preclinical * Red Source: antigen: Slide = Benign arrow # 6Smith-Jones preclinical indicates Data expression studies difference P, of Vallabhajosula PSMA in nude between found mice S, inmeans bearing Navarro this organ inLNCaP group V, Bastidas ishuman significant D,prostate Goldsmith ( P tumor. < 0
Slide 7: Heterogeneity of Antibody Deposition: Autoradiographs
Heterogeneity Autoradiographs Amount 5 J415 J591 7E11 n v Source: antigen: Slide mm = areas # 7Smith-Jones preclinical ofofnecrosis necrosis viable of and MAb tumor studies averaged P, stained Deposition Vallabhajosula insections 50% nude of mice the ofS,LNCaP bearing Navarro cross-sectional xenogra
Slide 8: Effective Focal Circumference of Lu-177 beta emission
Effective Focal Circumference 5 J415 J591 7E11 = Source: antigen: Slide mm circumference #areas 8Smith-Jones preclinical Tumor of localization ofof Targeting Lu-177 Lu-177 studies P, Vallabhajosula beta are in beta nude evident emission emission mice for S,helps bearing Navarro (3.2 eachovercome mm)
Slide 9: Clinical Experience with Lu-177 Humanized J591
Clinical Lu-177 Humanized Escalating Dose Maximum Repeated PSA 14 20 4 Median Source: antigen, Slide partial progressive stable responses: limiting # 9labeled Bander duration Experience in response disease doses doses tolerated patients J591 toxicity disease J591 NH, tolerated of (10-75 (PSA mAb (PS
Slide 10: Clinical Experience with Initial 7E11 Y-90 Studies
Clinical Initial 7E11 9 Significant Administration Reduction Source: following Slide mCi/m2 #mAb clinical 10 Kahn Experience radical dose of labeled hematologic PSA D, experience of administered Austin prostatectomy. aslope with chelating withY-90 JC, toxicity observed 7E11 with Maguire to using age
Slide 11: Clinical Experience: Human Anti-murine Antibody (HAMA) Response
Clinical Human In 0/10 1/18 The * Source: following Slide Based the prior incidence projected at#study a11 anti-murine ProstaScint Kahn Experience on protein radical aofHAMA D, protein of Y-90 dose Austin HAMA prostatectomy. studies antibodies with labeled serum dose of JC, 57E11 10 following mg for
Slide 12: Clinical Experience and Future Conclusions
Clinical Future Conclusions: Using Cytogen’s Slide #radionuclides aradioimmunotherapy 12 lower Experience current dose7E11 of with with 7E11 mAb 7E11 particulate mAb studies development MAbin emissions this patient initiative thatpopulation would addresses be more might bothlikely of investigate the
Slide 13: Preparation of 7E11 Conjugate with MeO-DOTA
Preparation Unconjugated MeO-DOTA Ret. Peak Area 6 1 1.86 8 0.44 7 2 98.14 Slide 99.56 .03 Time .74 .05 .79 (%) # 13 (min.) of7E11 7E11 the New Conjugate Conjugate
Slide 14: Radiolabeling and Immunoreactivity of 7E11 Conjugate
Incubation Radiolabeling % Slide ELISA 90 60 99.6 30 Lu-177 # 14 chelated timeand (minutes) Immunoreactivity
Slide 15: Select Future Therapies: Vaccine, ADC and Human mAbs
SelectVector Toxin Synthetic, Production Viral Novel Induces Completing Slide #conjugated Future alphavirus 15 both cell-killing ofpreclinical Vaccine: antibodies PSMA clinical-grade vaccine fully Therapies auristatin human development and killer antibodies mAbs: ADC T cells activities payloads unde